The present disclosure relates to a bioparticle measuring method including forming on a solid phase a complex of a sample containing a bioparticle sampled from a specimen, a capturer containing a tag which binds to the solid phase and capable of binding to the bioparticle, and a detector capable of binding to the bioparticle and containing a labeled substance. A part or the whole of the complex may be dissociated from the solid phase to prepare a measurement sample containing a part or the whole of the complex not fixed on the solid phase, and signals from the measurement sample may be detected by a particle analyzer.

An object of the present invention is to provide a cell population comprising adherent cells having low differentiation capacity derived from a fetal appendage, methods for producing or using the same, and a pharmaceutical composition comprising the cell population, in particular wherein the proportion of CD73- and CD90-positive adherent cells derived from a fetal appendage is 90% or more; and the cell population satisfies a relative expression level of LFA-3 gene to the expression level of SDHA gene of 1.0 or more, in particular wherein the relative expression level of HAPLN1 gene to the expression level of SDHA gene is 4.0 or more and/or the relative expression level of CCND2 gene to the expression level of SDHA gene is 1.5 or less, in particular wherein the proportion of the STRO-1-negative adherent cells derived from a fetal appendage is 95% or more.

Provided is a method for isolating a ureteric bud tip cell from cells, a tissue, or an organoid comprising the ureteric bud tip cell, comprising the following steps of contacting the cells, tissue, or organoid comprising the ureteric bud tip cell with a very low density lipoprotein receptor (VLDL-R) binding agent, and isolating the ureteric bud tip cell using the binding agent as an indicator.

The present invention relates to nucleic acid molecules comprising a nucleic acid sequence encoding a membrane-bound biotin mimetic peptide (BMP) or biotin acceptor peptide (BAP). The invention also relates to a method for selection of high producer cells secreting a protein of interest.

According to an embodiment of the present invention, there is provided a method of screening a prostate cancer patient by optical image analysis of a circulating tumor cell marker and a prostate-specific membrane antigen.

A lipid composition containing a nucleic acid, wherein the lipid composition comprises a peptide-lipid conjugate, is provided. The peptide of the peptide-lipid conjugates can be from 4 to 52 amino acids in length. Methods of using the lipid composition in the in vivo delivery of nucleic acids are further provided.

The invention relates to a method for detecting residual, undifferentiated pluripotent stem cells (PSCs) in a culture of cells differentiated from PSCs, the method comprising: culturing the cells on a substrate coated with laminin-521 and E-cadherin in a medium comprising a ROCK inhibitor; quantitating in the cultured cells expression of a marker of residual, undifferentiated PSCs; and comparing the marker expression in the cultured cells with the marker expression in a reference culture of cells comprising a known proportion of PSCs, wherein lower marker expression in the culture of cells than marker expression in the reference culture of cells indicates absence of residual, undifferentiated PSCs in the cultured cells or presence of residual, undifferentiated PSCs in the cultured cells at a proportion lower than the known proportion of PSCs in the reference culture of cells. The invention also relates to a method for manufacturing a therapeutic composition and a method for treating or preventing a condition in a subject.

The present disclosure relates to a bioparticle measuring method including detecting a signal from a first measurement sample and a signal from a second measurement sample, wherein the first measurement sample is prepared by mixing a first sample containing a bioparticle sampled from a specimen with a detector capable of binding to the bioparticle and containing a labeled substance, in the presence of an inhibitor capable of binding to the bioparticle and containing none of the labeled substance. The second measurement sample is prepared by mixing a second sample sampled from the same specimen independently from the first sample with the detector, under a condition that the inhibitor is substantially absent. A measurement result is then calculated from the detected signals from the first and second measurement samples.

Populations of cells enriched in fetal cells from a biological sample obtained from a pregnant subject are prepared using microbubbles, resulting in a sufficient number of fetal cells having a quality suitable for sequencing and providing non-invasive prenatal diagnosis of genetic disorders.

The present disclosure provides materials and methods for the delivery of therapeutic nucleic cells (and imaging agents) to tissues.